# KyNexis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kynexis-b-v

- Industry: Pharmaceuticals
- Headquarters: Naarden, Netherlands
- Website: www.kynexistx.com
- Total disclosed funding: $107M
- Latest round: Series A (Aug 19, 2026)
- Investors on record: 4

## About

Based in Naarden, Netherlands, and 2023, and co-founded by Carol Tamminga, Robert Schwarcz, and Kees Been is the CEO. KyNexis B.V. operates as a biotechnology company that offers therapeutic solutions to improve brain function, particularly cognitive impairment associated with schizophrenia. In August 2026, KyNexis B.V. raised EUR 40 million in series A funding led by Novartis Venture Fund, with participation from Sunstone Life Science Ventures, Forbion, and Ysios Capital Partners.

Kynexis is a biotechnology company developing precision therapeutics for brain diseases, with a focus on cognitive impairment associated with schizophrenia (CIAS). They are taking a biomarker-based approach to identify patients most likely to benefit from their potential new therapy, which targets KAT-II, a key enzyme in the kynurenine pathway. Kynexis is led by an accomplished team of industry experts, and they are committed to transforming the treatment paradigm of schizophrenia.

The company plans to use the August 2026 funding to complete Phase 2 work on KYN-5356 and prepare for later-stage clinical studies.

## Funding rounds

- Series A, Aug 19, 2026, $46M — Novartis Venture Fund, Forbion, Ysios Capital Partners, Sunstone Life Science Ventures
- Series A, Nov 7, 2023, $61M — Forbion, Ysios Capital Partners, Sunstone Life Science Ventures

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series A
- Sunstone Life Science Ventures (https://capitalatlas.ai/funds/sunstone-life-science-ventures) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A